| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | UBE2D1 |
| Uniprot No | P51668 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-147aa |
| 氨基酸序列 | MALKRIQKELSDLQRDPPAHCSAGPVGDDLFHWQATIMGPPDSAYQGGVF FLTVHFPTDYPFKPPKIAFTTKIYHPNINSNGSICLDILRSQWSPALTVS KVLLSICSLLCDPNPDDPLVPDIAQIYKSDKEKYNRHAREWTQKYAM |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于UBE2D1重组蛋白的3篇代表性文献摘要(注：文献信息为模拟示例，实际文献需通过数据库检索)：
---
1. **文献名称**: "Structural insights into UBE2D1-mediated ubiquitination"
**作者**: Zhang Y, et al.
**摘要**: 解析了UBE2D1重组蛋白的晶体结构，揭示了其与泛素E3连接酶RING结构域结合的分子机制，阐明了UBE2D1在底物泛素化中的催化位点及构象变化。
---
2. **文献名称**: "UBE2D1 promotes β-catenin degradation via Wnt signaling pathway"
**作者**: Li H, et al.
**摘要**: 研究发现重组UBE2D1通过促进β-catenin的泛素化降解抑制Wnt信号通路，在结肠癌细胞中证实其过表达可抑制肿瘤生长，提示UBE2D1作为潜在抑癌因子。
---
3. **文献名称**: "Functional characterization of UBE2D1 in Parkinson’s disease models"
**作者**: Smith J, et al.
**摘要**: 利用重组UBE2D1蛋白验证其与Parkin蛋白的协同作用，证明其通过增强线粒体自噬相关蛋白的泛素化，缓解帕金森病模型中神经元损伤。
---
如需具体文献，建议通过PubMed或Web of Science检索关键词“UBE2D1 recombinant protein”“UBE2D1 ubiquitination”获取最新研究。
**Background of UBE2D1 Recombinant Protein**
UBE2D1 (Ubiquitin-Conjugating Enzyme E2 D1) is a member of the E2 ubiquitin-conjugating enzyme family, which plays a central role in the ubiquitin-proteasome system (UPS). This system governs protein degradation, a tightly regulated process critical for maintaining cellular homeostasis, signal transduction, and stress responses. UBE2D1 facilitates the transfer of ubiquitin molecules from E1 ubiquitin-activating enzymes to substrate proteins, often in collaboration with E3 ubiquitin ligases. This post-translational modification, known as ubiquitination, can mark target proteins for proteasomal degradation or modulate their activity, localization, or interactions.
The recombinant UBE2D1 protein is produced through genetic engineering, typically expressed in *E. coli* or mammalian systems, ensuring high purity and activity for experimental use. Its structure includes a conserved catalytic core domain (UBC domain) essential for ubiquitin binding and thioester bond formation. UBE2D1 exhibits broad substrate promiscuity, enabling interactions with multiple E3 ligases, such as MDM2. Parkin, and TRAF6. making it a versatile tool in studying diverse pathways, including DNA repair, immune regulation, and apoptosis.
Research highlights UBE2D1's involvement in diseases like cancer and neurodegenerative disorders. For example, it contributes to the degradation of tumor suppressors (e.g., p53) and regulates NF-κB signaling. Its recombinant form is widely used in *in vitro* ubiquitination assays, enzyme kinetics studies, and drug discovery to identify UPS-targeted therapeutics. Unlike other E2 isoforms (e.g., UBE2D2-D4), UBE2D1 shows unique preferences for specific lysine residues (e.g., K48 or K63 linkages), influencing polyubiquitin chain topology and downstream outcomes.
Overall, UBE2D1 recombinant protein serves as a critical reagent for dissecting UPS mechanisms and developing therapies targeting protein turnover dysregulation.
×
